Cargando…
A Review of Nitric Oxide for the Treatment of Glaucomatous Disease
Glaucoma is the leading cause of irreversible blindness worldwide, affecting 64.3 million people. An estimated 60.5 million people are affected by primary open angle glaucoma globally, and this will increase to 111.8 million by 2040. The definition of glaucoma has evolved greatly over time. Although...
Autores principales: | Aliancy, Joah, Stamer, W. Daniel, Wirostko, Barbara |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Healthcare
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5693832/ https://www.ncbi.nlm.nih.gov/pubmed/28584936 http://dx.doi.org/10.1007/s40123-017-0094-6 |
Ejemplares similares
-
Regulation of Nitric Oxide Production by δ-Opioid Receptors during Glaucomatous Injury
por: Husain, Shahid, et al.
Publicado: (2014) -
On Glaucomatous Affections, and Their Treatment by Iridectomy
por: Bowman, W.
Publicado: (1865) -
Citicoline – a neuroprotector with proven
effects on glaucomatous disease
por: Iulia, Chitu, et al.
Publicado: (2017) -
A Narrative Review of Ocular Surface Disease Related to Anti-Glaucomatous Medications
por: Zhou, Xiaoyu, et al.
Publicado: (2022) -
The Role of Mitophagy in Glaucomatous Neurodegeneration
por: Stavropoulos, Dimitrios, et al.
Publicado: (2023)